Dexamethasone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dexamethasone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Dexamethasone is a potent synthetic glucocorticoid; the original approved indication text and detailed mechanism-of-action data were not available in this evidence pack. The TxGNN model predicts it may be effective for Alopecia Areata, and while the 13 retrieved clinical trials are largely unrelated oncology combination-therapy studies, 20 publications — including one RCT and several systematic reviews/cohort studies — directly support dexamethasone (oral/IV pulse therapy) as an existing off-label treatment for alopecia areata.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no license text or original_indications data available; MOA marked as data gap) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug in the evidence pack. Based on known pharmacological class information, dexamethasone is a high-potency synthetic glucocorticoid with broad systemic anti-inflammatory and immunosuppressive activity — this is not part of the structured evidence but is well-established background knowledge that contextualizes the prediction below.
Alopecia areata is an autoimmune disease in which cytotoxic T-cells attack the hair follicle, collapsing its normal immune-privileged state and triggering non-scarring hair loss. Systemic corticosteroids — including dexamethasone oral or IV pulse regimens — are already an established standard/second-line clinical treatment for moderate-to-severe alopecia areata, particularly in patients who are ineligible for or lack access to JAK inhibitors. This means the mechanistic link is not a purely theoretical model extrapolation: it is corroborated by real-world clinical practice and published pulse-therapy protocols identified in the literature evidence below.
By contrast, most of the clinical trials returned by the evidence search (e.g., dexamethasone used as a chemotherapy combination partner in multiple myeloma, NSCLC, or mesothelioma regimens) are not relevant to alopecia areata and reflect dexamethasone's routine use as an oncology-supportive medication rather than evidence for this specific repurposing hypothesis.
Clinical Trial Evidence
None of the retrieved trials directly investigate dexamethasone for alopecia areata; they largely reflect dexamethasone's role as a combination/supportive agent in oncology regimens and were graded as low relevance (C) where reviewed. They are listed below for transparency.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00282087 | Phase 2 | Completed | 47 | Adjuvant gemcitabine/docetaxel + doxorubicin in uterine leiomyosarcoma; not AA-related |
| NCT02004275 | Phase 1/2 | Unknown | 118 | Pomalidomide + dexamethasone ± ixazomib in relapsed multiple myeloma; dexamethasone as standard chemo co-agent, unrelated to AA |
| NCT02288078 | Phase 2 | Unknown | 74 | Prophylactic oral dexamethasone for regorafenib-induced fatigue/malaise in mCRC; unrelated to AA |
| NCT04343560 | N/A | Completed | 380 | Dexamethasone suppression test in mild autonomous cortisol secretion and bone strength; diagnostic use, not AA treatment |
| NCT01215916 | Phase 1 | Completed | 39 | LY573636 + pemetrexed in solid tumors; dexamethasone likely premedication only |
| NCT01126736 | Phase 1/2 | Completed | 98 | Eribulin + pemetrexed in NSCLC; unrelated to AA |
| NCT01607554 | Phase 1/2 | Terminated | 2 | Irinotecan in ISG15-high NSCLC; unrelated to AA |
| NCT01055496 | Phase 1 | Completed | 103 | R-CVP/R-GDP + inotuzumab in CD22+ NHL; dexamethasone as part of standard chemo backbone |
| NCT01866449 | Phase 2 | Completed | 24 | Cabazitaxel in temozolomide-refractory GBM; dexamethasone used for cerebral edema control, unrelated to AA |
| NCT02685826 | Phase 1/2 | Completed | 56 | Durvalumab + lenalidomide ± dexamethasone in newly diagnosed multiple myeloma; unrelated to AA |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36086930 | 2022 | RCT | Dermatologic Therapy | Randomized trial: low-dose dexamethasone oral mini-pulse vs. DPCP contact sensitization in severe pediatric alopecia areata |
| 39042154 | 2024 | Systematic Review / NMA | Archives of Dermatological Research | Network meta-analysis comparing systemic steroids, oral JAK inhibitors, and contact immunotherapy for severe AA |
| 16707886 | 2006 | Comparative Study | Dermatology (Basel) | Compares efficacy, relapse rate, and side effects across three systemic corticosteroid modalities for AA |
| 36461625 | 2023 | Review | Pediatric Dermatology | Review of pulse-dose corticosteroid dosing/administration regimens for AA in children |
| 36070222 | 2022 | Multicentric Study/Review | Dermatologic Therapy | Multicentric study of mini-pulse oral dexamethasone for moderate-to-severe AA |
| 35330017 | 2022 | Prospective Cohort | Journal of Clinical Medicine | Real-world cohort assessing effectiveness/safety of dexamethasone mini-pulse therapy in AA, plus response predictors |
| 41872082 | 2026 | Cohort | European Journal of Dermatology | Stepwise topical corticosteroid + dexamethasone rescue strategy enhances baricitinib outcomes in severe AA (n=19) |
| 17656876 | 2002 | Review/Commentary | Indian J Dermatol Venereol Leprol | Discussion of dexamethasone pulse therapy utility for extensive AA |
| 31579982 | 2019 | Case Series | Dermatologic Therapy | Combined IV pulse + topical corticosteroid for severe pediatric AA; comparison of 1-day vs. 3-day dexamethasone pulse regimens (n=73) |
| 10535249 | 1999 | Case Series | Journal of Dermatology | Twice-weekly 5mg dexamethasone oral pulse in extensive AA (n=30), early foundational protocol |
Germany Market Information
Dexamethasone currently has no registered marketing authorization in the evidence pack (market status: Not Marketed, 0 authorizations). No license records were available to summarize.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (see Data Gap DG001, classified as Blocking for safety pre-assessment).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Dexamethasone pulse therapy for alopecia areata is supported by an existing evidence base beyond the TxGNN score alone — including one RCT, a systematic review/network meta-analysis, and multiple cohort/case-series studies — indicating this is an established off-label practice rather than a purely model-generated hypothesis. However, the underlying evidence pack lacks the original indication text, MOA detail, and TFDA/BfArM safety labeling needed for a full safety assessment, so progression must be gated on closing these gaps.
To proceed, the following is needed:
- TFDA/BfArM package insert warnings and contraindications (Blocking gap DG001) — required before S1 safety pre-assessment can proceed
- Mechanism of action detail via DrugBank query (High-priority gap DG002)
- Confirmed original indication list and formal drug classification (currently absent from the evidence pack)
- Drug-drug interaction data (current DDI query status: not found)
- Given the trial evidence is oncology-combination based and not AA-specific, no further AA-specific trial evidence is expected from ClinicalTrials.gov; reliance should remain on the published literature base above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.